Novo Holdings REPAIR Impact Fund invests USD12m in Mutabilis and IBT Vaccines
The Novo Holdings REPAIR Impact Fund has made a EUR7 million investment in Mutabilis, a company developing novel antibacterials against Gram-negative infections based near Paris, France.
This investment will allow the company to accelerate its 2G-Dabocins program, a wide spectrum Gram-negative anti-infective agent, which is currently undergoing lead optimisation.
Display your AMR technology / product:
Global AMR Technologies Database
- Preventive – Diagnostic – Antimicrobial technologies
- Academia – Research Institutes – Start ups – SMEs – Multinationals
- Early research <-> near market
- Global reach for funding / co-development / licensing